Curis Begins Phase 1 Trial of Anti-Tumor Drug
Drug developer Curis (NASDAQ:CRIS), of Cambridge, MA, reported today that it has begun a Phase 1 clinical trial of an anti-cancer small molecule, dubbed CUDC-101. The experimental drug is designed to inhibit tumor cell growth and survival, and 18 to 40 patients are expected to enroll in the clinical trial.
More from EXOME
Trending on Xconomy
By posting a comment, you agree to our terms and conditions.
Underwriters and Partners
Xpertise: Watch + Learn
-
From Our Editors · Video
Interview with Lita Nelsen on the Future of Technology Transfer
Lita Nelsen recently retired as the long-time director of MIT’s Technology Licensing Office.
-
Sponsored · Whitepaper
Information Technology Industry Spotlight Report
Investing in growth will continue to power the IT M&A cycle going forward
RSM -
Xconomy Insight · Webinar
Building Out the Biotech Team for Investment & Development Success
Join us for this exclusive FREE webinar!